Alnylam Pharmaceuticals, Inc. (ALNY) Guidance & Earnings Results
On 2026-07-30 Alnylam Pharmaceuticals, Inc. lowered guidance: "FY2026 TTR net product revenue guidance reduced from $4,400-$4,700M to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALNYAlnylam Pharmaceuticals, Inc.Follow ALNY — free
—
Price chart with a free account
- Market cap
- 30.0B
- P/E TTM
- 41.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | Lowered | FY2026 TTR net product revenue guidance reduced from $4,400-$4,700M to $4,200-$4,500M · full year |
| 30 Apr 26 | Reaffirmed | FY2026 combined net product revenues $4,900-$5,300M; TTR $4,400-$4,700M · full year |
| 12 Jan 26 | Raised | 2026 net product revenue guidance $4,900-5,300M vs 2025 preliminary $2,987M (71% growth at midpoint) |
| 30 Oct 25 | Raised | TTR franchise guidance raised to $2.475-$2.525B; total net product revenues to $2.95-$3.05B (+10% midpoint) · full year |
| 31 Jul 25 | Raised | FY2025 TTR franchise net revenues raised to $2,175M-$2,275M; total net product revenues raised to $2,650M-$2,800M (from $2,075M-$2,225M); 27% midpoint increase. · full year |
Alnylam Pharmaceuticals, Inc. — questions
- What guidance did Alnylam Pharmaceuticals, Inc. give?
- On 2026-07-30: "FY2026 TTR net product revenue guidance reduced from $4,400-$4,700M to $4,200-$4,500M"
- When does Alnylam Pharmaceuticals, Inc. report earnings?
- Alnylam Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Alnylam Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.